ARG23002
anti-CD16/CD32 antibody [FCR4G8]
anti-CD16/CD32 antibody [FCR4G8] for Flow cytometry and Mouse
Developmental Biology antibody; Immune System antibody; General Lymphocyte Marker Study antibody; Natural killer cells antibody
Overview
| Product Description | Rat Monoclonal antibody [FCR4G8] recognizes CD16/CD32 Rat anti Mouse CD16/CD32 antibody, clone FCR4G8 recognizes an epitope expressed by the murine low affinity Fc receptors, Fc gamma III (CD16) and Fc gamma II (CD32). In the mouse only the transmembrane form of CD16 is reported to exist, which is expressed on macrophages, NK cells, granulocytes, myeloid precursors, and subpopulations of T lymphocytes. CD32 is primarily expressed on cells of the myeloid lineage and also on mature B lymphocytes. |
|---|---|
| Tested Reactivity | Ms |
| Tested Application | FACS |
| Host | Rat |
| Clonality | Monoclonal |
| Clone | FCR4G8 |
| Isotype | IgG2b |
| Target Name | CD16/CD32 |
| Antigen Species | Mouse |
| Immunogen | PU5 1.8 IOE7 Balb/c Mouse cell line. |
| Conjugation | Un-conjugated |
| Alternate Names | FCRIIIA; FcRIIIa; CD antigen CD16a; Fc-gamma RIII-alpha; FCR-10; FcR-10; FCRIII; FCG3; Low affinity immunoglobulin gamma Fc region receptor III-A; FCGRIII; CD16; Fc-gamma RIIIa; IgG Fc receptor III-2; IMD20; CD16A; IGFR3; CD16a antigen; FCGR3; FcRIII; Fc-gamma RIII |
Application Instructions
| Application Suggestion |
|
||||
|---|---|---|---|---|---|
| Application Note | FACS: Use 10 µl of the suggested working dilution to label 10^6 cells in 100 µl. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Purification with Protein G. |
| Buffer | PBS and 0.09% Sodium azide |
| Preservative | 0.09% Sodium azide |
| Concentration | 1 mg/ml |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Gene Symbol | Fcgr3 |
|---|---|
| Gene Full Name | Fc receptor, IgG, low affinity III |
| Background | This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] |
| Function | Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis. [UniProt] |
| Highlight | Related products: CD16 antibodies; CD16 ELISA Kits; CD16 Duos / Panels; Anti-Rat IgG secondary antibodies; Related news: Tumor-Infiltrating Lymphocytes (TILs) |
| Research Area | Developmental Biology antibody; Immune System antibody; General Lymphocyte Marker Study antibody; Natural killer cells antibody |
| Calculated MW | 29 kDa |
| PTM | Glycosylated. Contains high mannose- and complex-type oligosaccharides. Glycosylation at Asn-180 is mandatory for high affinity binding to the Fc and for discrimination between fucosylated and afucosylated IgG glycoforms. The soluble form is produced by a proteolytic cleavage. |
